Highest-materiality recent filing
TJX Q2 FY27 EPS $1.36 beats, comps +4%; raises FY27 EPS and margin guidance
Q2 net sales $15.2B (+5% YoY); comp sales +4% above plan; diluted EPS $1.36 (+24%), adjusted $1.22 (+11%).
TJX shareholders elect all 10 director nominees, ratify auditor, approve say-on-pay
All 10 director nominees elected with majority support; no nominee received less than 85% of votes cast.
TJX Q1 FY27 EPS $1.19 beats plan, comp sales +6%; raises full-year guidance
Q1 diluted EPS $1.19 (+29% YoY) on net sales $14.3B (+9%), pretax margin 12.0% (+1.7 ppts), all well above plan.
TJX Q4 adj. EPS $1.43, comp +5% beat plan; dividend up 13%; FY27 buyback $2.5-$2.75B
Q4 comp sales +5% well above plan; adj. EPS $1.43 (+16% YoY); net sales $17.7B (+9%).
TJX Q3 FY26 beats: comp +5%, EPS $1.28 (+12%); raises full-year guidance
Q3 consolidated comp sales +5%, net sales $15.1B (+7% YoY); diluted EPS $1.28 vs $1.14 (+12%).
TJX Q2 EPS $1.10 beats plan, comp sales +4%, raises FY26 EPS guidance to $4.52-$4.57
Q2 net sales $14.4B (+7% YoY); consolidated comp sales +4%, above plan; diluted EPS $1.10 (+15% vs $0.96).
TJX annual meeting: All director nominees elected, auditor ratified, say-on-pay approved
All 10 director nominees elected with large majorities (lowest 863M for, 80M against for Amy B. Lane).
TJX Q1 EPS $0.92 beats plan; comps +3%; maintains FY26 guidance
Q1 net sales $13.1B (+5% YoY); consolidated comp sales +3% at high end of plan.
TJX amends revolving credit facilities; extends maturities to 2029/2030, maintains $1.5B capacity
Amended $500M facility to $750M with maturity extended to May 9, 2029.
TJX Q4 comps +5%, EPS $1.23 beat; guides FY26 EPS $4.34-$4.43, raises dividend 13%
Q4 diluted EPS $1.23, up 10% vs. prior-year adjusted $1.12; FY25 EPS $4.26, up 13% vs. adjusted $3.76.
CEO and President Ernie Herrman and Executive Chairman Carol Meyrowitz employment extended to January 29, 2028.
TJX Q3 FY25 EPS $1.14 beats plan; comps +3% at high-end; raises full-year guidance
Net sales $14.1B (+6% YoY); consolidated comp store sales +3% driven entirely by customer transactions.
TJX amends bylaws to add universal proxy rules and procedural updates for director nominations
Bylaws amended effective Sept 18, 2024 to address universal proxy rules per Rule 14a-19.
TJX Q2 EPS $0.96 beats plan; comps +4%; raises full-year outlook; invests $360M in Brands For Less
Q2 diluted EPS $0.96 (vs $0.85 last year, +13%), pretax profit margin 10.9% (+0.5pp), comp store sales +4%.
All 10 director nominees elected with strong support; lowest vote share was 88% for Amy B. Lane.
TJX Q1 comps +3%, EPS $0.93 (+22%), raises FY25 profit margin and EPS guidance
Q1 net sales $12.5B (+6% YoY); comp store sales +3% driven entirely by increased customer transactions.
TJX Q4 EPS $1.22 beats plans; comps +5%; guides FY25 EPS $3.94-$4.02
Q4 diluted EPS $1.22 (+37% YoY); adjusted EPS $1.12 (+26% YoY) on $16.4B revenue (+13%).
John Klinger promoted to Senior EVP, CFO effective Feb 4, 2024; base salary $825,000, MIP target 85%, LRPIP $450k, SIP target $2.9M.
TJX Q3 beats: comp sales +6%, EPS $1.03; raises FY24 comp and EPS guidance
Net sales $13.3B (+9% YoY), comp store sales +6% driven entirely by customer traffic; Marmaxx +7%, HomeGoods +9%.
TJX elects Vertex CFO Charles F. Wagner Jr. to its Board of Directors
Charles F. Wagner, Jr., EVP and CFO of Vertex Pharmaceuticals, elected to TJX Board and Audit & Finance Committee effective Sept 20, 2023.
TJX Q2 FY24 EPS $0.85 (+23%) beats plan; raises full-year guidance
Q2 net sales $12.8B (+8% YoY); overall comp store sales +6%, entirely traffic-driven.
Senior EVP Richard Sherr to retire July 14; enters consulting agreement through April 2024
Richard Sherr, Senior EVP, retiring July 14, 2023; will consult from Aug 1, 2023 to Apr 30, 2024.
TJX Q1 pretax margin 10.3% beats plan; EPS $.76; raises FY24 guidance
Net income $891M, diluted EPS $.76, up 55% YoY; adjusted EPS up 12% vs prior year adj. EPS of $.68.
TJX amends $500M and $1B credit facilities; extends $500M facility maturity to 2028
$500M revolving credit facility maturity extended from May 2024 to May 8, 2028.
Q4 diluted EPS $0.89, up 14% YoY; revenue $14.5B, up 5% YoY; U.S. comp sales +4% (above plan).
TJX Q3 EPS $0.91 beats; raises Q4 comp guidance; Marmaxx +3%
Net sales $12.2B (-3%); diluted EPS $0.91, adjusted $0.86; pretax margin 11.2%; all above plan.
John Klinger promoted to EVP, CFO effective Jan 29, 2023; will serve as principal financial and accounting officer.
Director John F. O'Brien resigns from TJX Board due to illness
John F. O'Brien resigned from the Board on November 9, 2022, effective immediately.
TJX Q2 EPS $0.69 meets high end; guides FY23 EPS down to $2.87-$2.95
Q2 net sales $11.8B (-2% YoY); U.S. comp store sales -5% vs +21% open-only comp last year.
TJX shareholders reject say-on-pay; approve stock plan with 27M new shares
Advisory say-on-pay vote failed: 48.7% for vs 49.4% against (excluding broker non-votes).
TJX Q1 adjusted EPS $0.68 beats plans; raises FY23 adjusted pretax margin outlook to 9.6%-9.8%
Q1 net sales $11.4B +13% YoY; U.S. comp flat, Marmaxx comp +3% driven by traffic.
TJX plans phased retirement of Senior EVP Richard Sherr through July 2023; transition to Mizzi
Sherr reduces to 80% schedule July 11, 2022; ceases as executive officer Jan 29, 2023; retires July 14, 2023.
TJX to divest 25% Familia stake after Russia invasion; potential $186M impairment
Commits to sell equity in Familia, a Russian off-price retailer with 400+ stores, due to Ukraine invasion.
TJX reports Q4 FY22 net sales $13.9B, EPS $0.78; raises dividend 13%, plans $2.25-$2.5B buyback
Q4 FY22 net sales $13.9B (+14% vs Q4 FY20); diluted EPS $0.78 vs $0.81 in Q4 FY20.
Ernie Herrman and Carol Meyrowitz entered into letter agreements extending their employment terms to February 1, 2025.
TJX Senior EVP Richard Sherr adopts Rule 10b5-1 trading plan
Plan allows exercise of options and/or sale of shares on open market starting at least 30 days after Nov 18, 2021.
TJX Q3 FY22 EPS $0.84 (+24% vs FY20); raises FY22 buyback to $1.75-2.0B
Net sales of $12.5B, +20% vs Q3 FY20; overall open-only comp store sales +14% vs Q3 FY20.
TJX Q2 FY22 beats plan: net sales $12.1B, open-only comp +20% vs FY20, EPS $0.64
Q2 FY22 net sales $12.1B (+23% vs Q2 FY20); diluted EPS $0.64 (includes $0.15 debt charge) vs $0.62 in Q2 FY20.
The agreements reflect Mr. Klinger’s promotion to Senior Executive Vice President, Chief Financial Officer, and Mr. Goldenberg’s transition to an executive advisory role, in each case effective February 4, 2024.
Mr. Goldenberg will no longer serve as an executive officer of TJX as of February 3, 2024
On September 20, 2023, the Board of Directors (the “Board”) of The TJX Companies, Inc. (the “Company”) elected Charles F. Wagner, Jr. as a member of the Company’s Board and of its Audit and Finance Committee, effective immediately.
On June 6, 2023, The TJX Companies, Inc. (the “Company”) entered into a letter agreement (the “Agreement”) with Richard Sherr, Senior Executive Vice President, pursuant to which Mr. Sherr agreed to provide consulting services to the Company following his scheduled retirement on July 14, 2023.
John Klinger, Executive Vice President, Corporate Controller, was promoted to Executive Vice President, Chief Financial Officer of The TJX Companies, Inc. (“TJX” or the “Company”), effective January 29, 2023
Scott Goldenberg, the Company’s current Chief Financial Officer, who on the Effective Date will assume the role of Senior Executive Vice President, Finance of the Company.
On November 9, 2022, John F. O’Brien, a member of the Board of Directors (the “Board”) of The TJX Companies, Inc., resigned from the Board, effective immediately, due to illness.
effective January 29, 2023, Mr. Sherr will continue to remain employed on this reduced schedule but will no longer serve as an executive officer of TJX, and his employment will continue as a Senior Executive Vice President until his scheduled retirement date of July 14, 2023.
Max materiality 0.85 · Median 0.75 · Most common event earnings